MedTrace Logo

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

NCT04417517 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2025-07-20

No results posted yet for this study

Summary

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).

Conditions

  • Higher Risk Myelodysplastic Syndromes

Interventions

DRUG

evorpacept

Fusion protein that blocks CD47-SIRPalpha pathway

DRUG

azacitidine

Hypomethylating agent (HMA)

Sponsors & Collaborators

  • ALX Oncology Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-02
Primary Completion
2025-01-17
Completion
2025-06-10
FDA Drug
Yes

Countries

  • United States
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04417517 on ClinicalTrials.gov